Paindetect online dating

The total cumulative patient exposure to 5% lidocaine-medicated plaster since marketing authorization was first obtained in 1999 has now reached approximately 23 million patients.

Its efficacy and safety in treating PHN have led to widespread use in other LNP syndromes, including diabetic distal polyneuropathy, post-surgical, and post-traumatic pain [].

Many clinical guidelines recommend this treatment modality as a first-line option for treating LNP, particularly in frail and/or elderly patients and those receiving multiple medications, because the benefit-to-risk ratios are far better than those of systemic analgesics.

However, some guidelines make only a weak recommendation for its use.

The 5% lidocaine-medicated plaster has been used for several years to treat LNP and is registered in approximately 50 countries.

Another probable mechanism is direct activation of the TRP (transient receptor potential) channels TRPV1 and TRPA1 expressed in nociceptive sensory neurons.

This produces analgesia by membrane depolarization, reducing the electrical activity in TRP-containing nerves [].

The following parameters were calculated for each study using intent-to-treat analysis: absolute risk reduction (proportion of control group with benefit minus proportion of treated group with benefit); number needed to treat (NNT) for adequate pain relief; 95% confidence interval for the NNT; and number needed to harm (NNH).

A score was then determined for each therapy based upon the quality of the studies (e.g., Class I evidence was provided by a prospective, randomized, controlled clinical trial with masked outcome assessment in a representative population).

Leave a Reply